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SUMMARY  Atopic eczema/dermatitis syndrome is a term that covers 
different subtypes of atopic dermatitis.  The “intrinsic” type of atopic 
dermatitis is non-IgE-associated, and the “extrinsic” type is IgE-asso-
ciated atopic eczema/dermatitis syndrome. In the etiopathogenesis of 
atopic dermatitis there are well known interactions among genetic, en-
vironmental, skin barrier, immune factors, and stress. Genetic factors 
determine the expression of atopic dermatitis as pure or mixed with 
concomitant respiratory or intestinal allergy, depending on genetic sus-
ceptibility. Immunologic abnormalities of type I and type IV reactions 
have been described in patients with atopic dermatitis. Immunologic 
triggers are aeroallergens, food allergens, microbial products, auto-
allergens and contact allergens. Immune reactions determine many 
features of atopic dermatitis. These immune reactions also include cell 
mediated or delayed hypersensitivity. The currently accepted model 
proposes a predominant Th2 cytokine milieu in the initiating stages 
of acute atopic dermatitis lesions, and a mixed Th1 and Th2 pattern 
in chronic lesions. A two-phase model includes Th2 initiation with at-
traction of macrophages and eosinophils, which in turn produce in-
terleukin 12 that is the activator of Th1 type response. Atopic derma-
titis skin contains an increased number of IgE-bearing Langerhans 
cells which bind allergens via the high-affinity IgE receptor (FcεRI). 
Langerhans cells play an important role in cutaneous allergen presen-
tation to Th2 cells via major histocompatibility molecules. Eosinophilia 
and IgE production are influenced by type 2 cytokines. Degranulation 
of eosinophils occurs in the dermis with the release of toxic proteins 
such as major basic protein and could account for much of the inflam-
mation. Mast cells are increased in number and produce mediators 
other than histamine that induce pruritus and may have an effect on 
interferon γ expression. Mast cells produce a number of proinflamma-
tory cytokines. There is an elevated production of prostaglandin E2 
by peripheral monocytes. Prostaglandin E2 has at least two potential 
roles in the initiation of atopic dermatitis. Firstly, it reduces interferon-γ 
production by T helper cells, thereby favoring the initial, dominant Th2 
immune response; and secondly, it directly enhances IgE production 
by B lymphocytes with an increased secretion of interleukin 4, interleu-
kin 5 and interleukin 13. Many lesions of atopic dermatitis result from 
scratching, thus it is tempting to speculate that immune perturbations 
in genetically predisposed individuals provoke the release of local pru-
ritogens and keratinocyte-derived cytokines, which then further exac-
erbate the previously described immune response.
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 INTRODUCTION
 Atopic dermatitis (AD) is a chronically relaps-
ing, highly pruritic, inflammatory skin disease. AD 
is associated with a genetic predisposition to im-
mune system dysregulation. AD is often associ-
ated with a personal or family history of atopy such 
as asthma and/or allergic rhinitis, or AD itself (1,2). 
The “extrinsic” form of AD is associated with IgE-
mediated sensitization and involves 70%-80% of 
patients.  The “intrinsic” form of AD does not imply 
IgE-mediated sensitization and involves 20%-30% 
of patients (3,4). It is classified under “nonatopic 
eczema” (5). Eosinophilia is associated with both 
forms of AD (3). “Intrinsic” AD is associated with 
less interleukin-4 (IL-4) and IL-13 production than 
“extrinsic” AD (3). AD may affect 20% or more chil-
dren in westernized societies, making it one of the 
most common of all noninfectious childhood ail-
ments (6). Around 85% of affected individuals de-
velop the disease before 5 years of age (1). More 
than 25% of children in northern Europe are af-
fected (7). There is an especially high prevalence 
in children and infants (8,9). AD may persist into 
adulthood in up to 60% of patients (2,10). The 
prevalence of AD in adults is 1%-3%. Its preva-
lence has increased two- to threefold during the 
past three decades in industrialized countries but 
remains much lower in countries with predomi-
nantly rural or agricultural areas, such as former 
socialist countries like Albania (3,11). The Eczema 
Area and Severity Index (EASI) is used by der-
matologic investigators worldwide to assess the 
eczema disease severity.  The Self-Administered 
EASI (SA-EASI) was found to be a valid measure 
of AD severity in old age groups (12). In future 
studies, SA-EASI will permit relationship analysis 
of the skin disease severity to measures such as 
quality of life, disability, patient satisfaction, and 
the costs of various therapies (12).  
 Complex interactions among genetic, envi-
ronmental, skin barrier and immunologic factors, 
stress and other emotional problems contribute to 
the pathogenesis of AD. AD is associated with typ-
ical clinical features according to Hanifin and Ra-
jka, and significant changes in several important 
factors of cellular and humoral immunity including 
increased IgE levels, eosinophil cationic protein 
(ECP), CD4 depressed CD8, altered peripheral 




 AD is a complex polygenic disorder, and sev-
eral candidate genes have been indentified as 
being associated with AD. Interactions between 
genes and environmental factors contribute to the 
genesis of atopy (13,14). A number of these chro-
mosomes contain genes for various interleukins, 
major histocompatibility complex proteins, and a 
component for the high-affinity IgE receptor (Fc-
εRI) (13). Studies have identified regions of ge-
netic linkage on chromosomes 1,2,3,4,5,6,7,11,1
2,13,16 and 17 (13,14).
 It was demonstrated that the “extrinsic” and 
“intrinsic” forms of AD differ significantly according 
to the IL-4 and IL-4 receptor (IL-4R) genes. Ac-
cording to Tanaka et al., polymorphisms in the IL-4 
gene and the IL-4 receptor alpha chain gene play 
no role in the development of AD in patients who 
have normal IgE productivity (15). The IL-4 gene 
is located on chromosome 5, and IL-4R alpha 
chain gene on chromosome 16. Polymorphisms in 
these genes play a role in the development of AD 
in patients who have elevated IgE but not in those 
who have normal IgE (15). The gene for β-2-adr-
enoreceptor is located on chromosome 5q31-33 
in asthma patients (16). The genes for the cluster 
family of Th2 cytokines, i.e. IL-3, IL-4, IL-5, IL-13 
and granulocyte-macrophage colony stimulating 
factor (GM-CSF) are also located on chromosome 
5q31-33 (3,17). The gene for Fc fragment of the 
IgE high affinity receptor (FcεR1B) is located on 
chromosome 11q12-q13 (18,19). FcεR1B is re-
sponsible for initiating allergic response on mast 
and other cells. On chromosome 12q13-q24, the 
following genes are located: signal transducer and 
activator of transcription 6 (STAT 6), interferon-
gamma (IFNγ), mast cell growth factor (MGF), leu-
kotriene A4 hydrolase (LTA4H), insulin-like growth 
factor 1 (IGF1), and nuclear transcription factor 
Y beta chain (NFYB) (19). STAT 6 is involved in 
IL-4-induced commitment of CD4+ T cells to the 
Th2 type and IgE isotype switching in B cells. IFNγ 
promotes differentiation of Th1 lymphocytes, and 
inhibits differentiation and IL-4 production in Th2 
cells (19). MGF controls proliferation of hemato-
poietic stem cells and mature mast cells; LTA4H 
is involved in prostaglandin metabolism and in-
flammatory response;  IGF1 promotes differentia-
tion of both B and T lymphocytes; and NFYB up-
regulates the transcription of IL 4 (19). The gene 
for costimulatory molecules CD86 and CD80 is 
located on chromosome 3q21. These molecules 
may modulate T cell responses (3). Chromo-
somes 1q21, 17q25, and 20p are also linked to AD 
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and are known to contain psoriasis susceptibility 
genes, which suggests common candidate genes 
involved in the control of skin inflammation (3).
 No clear linkage of atopy to HLA has been 
demonstrated so far. Recently, polymorphisms 
in the promotor region of RANTES (regulated on 
activation normal T cell expressed and secreted) 
and in the gene regulatory region of monocyte 
chemoattractant protein-1 (MCP-1) have been 
found to increase the expression of these chemo-
kines. The -40 3A allele of the RANTES promotor 
region was found to be associated with the atopy 
eczema/dermatitis syndrome (AEDS) in German 
children (20).
 SKIN BARRIER
 Stratum corneum (SC) is a distinctive two-
compartment system consisting of corneocytes 
and lipid-enriched extracellular matrix. Corneo-
cytes are formed by terminal differentiation of 
keratinocytes, which includes cross-linking of 
proteins such as liricrin and involucrin by trans-
glutaminase to form the cornified envelope, as 
well as the loss of DNA and internal organelles. 
Corneocytes provide mechanical resistance. The 
extracellular matrix lipids are organized into lamel-
lar membranes enriched with free fatty acids, cho-
lesterol and ceramides. They are derived from the 
lamellar body content secretion. The extracellular 
matrix lipids are responsible for the permeability 
barrier. There is an intrinsic defect in the keratino-
cyte barrier function. A decreased skin barrier is 
associated with reduced ceramide levels, reduced 
urea content in SC, reduced natural moisturizing 
factor, reduced level of pyrrolidone carboxylic acid 
and water soluble amino acids, which reflects as 
a decreased profilaggrin production and therefore 
enhanced transepidermal water loss (21-23).  In 
particular, ceramides are the major water-retain-
ing molecules in the extracellular space of the cor-
nified envelope (3). A reduced content of cerami-
des has been reported in the cornified envelope of 
both lesional and nonlesional skin in AD patients 
(3). None the less, this skin barrier function impair-
ment in AD leads to numerous insults which act as 
triggers of inflammation. These include irritants, 
allergens, autoallergens, and microbes (3).
 The increased susceptibility to irritants in AD 
may therefore represent a primary defect of epi-
dermal differentiation compounded by the pres-
ence of inflammation-induced skin damage (3). 
Temperature, humidity, and fabrics texture, sweat-
ing, and occlusive clothing can modulate the effect 
of irritants (16,21). The increased antigen absorp-
tion contributes to cutaneous characteristics of AD 
hyperreactivity (3).
 ALLERGENS
 Allergic responses to environmental allergens 
can develop, and the microbes and yeasts that 
may contribute to the inflammatory process in AD 
are Staphylococci and Pityrosporum (24). Food 
allergens can induce eczematoid rashes in about 
40% of children with moderate to severe AD (3). 
Studies suggest that food allergies are most likely 
to be important in a subset of young children, usu-
ally under the age of three years, with cow’s milk, 
egg, peanuts, soy, and wheat as most common 
allergens (11). Food allergy has a role in at least 
20% of the cases of AEDS in children younger 
than four years (25). In patients with cow’s milk 
allergy and AEDS resolution occurs in 90% by the 
age of four. The presence of cow’s milk allergy 
during infancy increases the risk of development 
of other food allergies, respiratory atopy, and per-
sistence of AEDS. Adverse reactions to bovine 
proteins have an important role in AEDS (25). 
Restriction of antigenic foods during lactation and 
early life has shown benefit in some prospective 
studies (26). Although breastfeeding should be 
recommended for all infants, it does not prevent 
eczema in children with a genetic risk (27). Paren-
tal eczema is the major risk factor for eczema. In 
a subset of these patients, urticarial reactions or 
noncutaneous symptoms will ensue that can trig-
ger the itch-scratch cycle that flares this condition. 
Children with food allergies generally have posi-
tive immediate skin tests or serum IgE directed to 
various foods, particularly eggs, milk, wheat, soy 
and peanuts, even though they have normal total 
serum IgE levels (3). There is also a significant 
increase in plasma histamine levels and eosino-
phil activation. Food allergen-specific T cells have 
been cloned from skin lesions of AD patients (3).
 Most food allergic children outgrow their food 
hypersensitivity in the first few years of life, usu-
ally till the age of three, so food allergy is not a 
common trigger factor in older patients with AD. 
Afterwards, the sensitization to inhalant allergens 
may begin. Skin lesions can develop after inhala-
tion of aeroallergens (3). Epicutaneous application 
of aeroallergens by atopy patch test on uninvolved 
skin of AD patient elicits eczematoid reactions in 
30%-50% of patients (3). The degree of IgE sensi-
tization to aeroallergens is directly associated with 
the severity of AD (3). Human proteins can act as 
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autoallergens in patients with severe AD, and IgE 
immune complexes can be detected in AD sera 
(3). Release of these autoallergens from dam-
aged tissues could trigger IgE or T cell-mediated 
responses (3). Therefore, environmental allergens 
can initiate IgE immune response but allergic in-
flammation can be maintained by the release of 
human proteins derived from damaged skin of 
chronic AD patient (3).
 Most patients with AD are colonized with 
Staphylococcus (S.) aureus (3,28). S. aureus is 
found in more than 90% of AD skin lesions in con-
trast to only 5% of normal subjects that harbor this 
organism. Acute inflammatory lesions have more 
S. aureus than chronic AD skin lesions or normal-
looking atopic skin.
 As already pointed out, atopic skin is deficient 
in ceramides, which is related to abnormal metabo-
lism of essential fatty acids. The generation of free 
fatty acids from phospholipids regulates secretory 
phospholipase A2, subsequently reflecting on pH, 
and regulates the activity of at least two enzymes 
in generating ceramides, acid sphingomyelinase 
and β-glucocerebrosidase. Fatty acids have mild 
antiseptic properties; their abnormally low levels 
in atopic skin may contribute to high levels of S. 
aureus (16,29,30). Bacterial ceramidase causes 
further ceramide reduction. 
 As demonstrated in experimental animal mod-
els, S. aureus binds to a significantly greater ex-
tent to skin sites with Th2-mediated skin inflam-
mation due to IL-4 (3). IL-4 appears to induce the 
synthesis of fibronectin (an important adhesin) 
and therefore to play a crucial role in the enhance-
ment of S. aureus skin binding.
 With the overgrowth of S. aureus, the inflam-
mation in AD skin is exacerbated or maintained 
by secreting a group of toxins known to act as su-
perantigens that stimulate marked activation of T 
cells and macrophages (S. aureus can activate up 
to 20% of all T-cells) (3,28).  S. aureus can pro-
duce other toxins that are likely to contribute to 
skin inflammation. Scratching due to dryness as 
a major cause of pruritus probably enhances S. 
aureus binding by disturbing skin barrier and ex-
posing extracellular matrix molecules known to 
act as adhesin (such as fibronectin, collagen); this 
is called the “itch-scratch cycle”. Specific IgE an-
tibodies directed against staphylococcal superal-
lergens are also produced and correlate with skin 
severity (31). S. aureus exacerbates or maintains 
skin inflammation in AD by inducing corticosteroid 
resistance (3). AD skin is also deficient in antimi-
crobial peptides needed for host defense against 
bacteria, fungi, and viruses (32,33). The lack of 
innate immune system predisposes these patients 
to viral and fungal infestations (3).
 The possible significance of the yeast Malas-
sezia (Pityrosporum ovale), particularly in AD lo-
cated in the head and neck region, is acting as an 
allergen inducing maturation of dendritic cells that 
are incapable of internalizing the yeast and there-
fore increasing the risk of skin infection (34,35). 
A study in AD patients revealed a correlation be-
tween skin prick test, patch test to P. ovale, and 
family history of atopic diseases, thus proving the 
role of immediate and contact hypersensitivity to 
P. ovale in the exacerbation of AD (36).
 ENVIRONMENTAL FACTORS
 The importance of environmental factors in 
the development of AD has been ever increasing 
for several reasons. First of all, the increase in the 
prevalence of AD cannot be explained by genetic 
factors, and a wide variation in its prevalence with-
in and between countries suggests that factors as-
sociated with “western lifestyle” maybe play a role 
(11). The “hygiene hypothesis” includes reduction 
of early childhood infectious diseases through 
vaccination and increased use of antibiotics. This 
would prevent the maturation of the immune sys-
tem and increase the risk of developing atopic dis-
eases (14,37). Furthermore, there is an increase in 
AD prevalence in people with similar genetic back-
grounds from less developed countries who move 
to industrialized countries (11). The mechanisms 
of action of environmental factors contributing to 
AD seem to include immune factors and suscep-
tibility to irritation or sensitization by other agents, 
and are currently being investigated (11). Whether 
timing of exposure to environmental factors is also 
important is still in the phase of research (11).
 The major environmental risk factors influ-
ence the development of allergy. They include 
smoking, indoor dampness, poor ventilation that 
tends to concentrate allergens indoors, ingestion 
of certain foods, and inadequate clothing (38-40). 
Several studies showed a greater risk of maternal 
vs paternal smoking (38,41). Passive smoking in 
early life is by far the best documented trigger for 
the development of allergy (38,42). Other environ-
mental risk factors include keeping of pets, floors 
with carpets (in childrens’ bedroom), which may 
be contaminated with high levels of domestic mite, 
animal dander, local pollens, mould, etc. Air pollu-
tion may exacerbate AD as well (43). Increased 
concentration of circulating immunocomplexes 
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was found in 80%, and of total IgE in 50% of AD 
patients sensitive to nickel (the most common al-
lergen in these patients) (44). The link between 
house dust mite (HDM) and AD remains less clear 
than the link between HDM and respiratory aller-
gy. Studies addressing HDM avoidance measures 
often fail to demonstrate a clinical benefit in AD 
(11,45).  
 Western lifestyle includes urbanization, devel-
opment, changes in diet, body weight, antibiotic 
use and stress (39,46-48).
 IMMUNOLOGY
 Besides early hypersensitivity, delayed hyper-
sensitivity type IV (cell-mediated immunity) is also 
involved in the pathogenesis of AD. The currently 
investigated pathogenetic aspects of AD include 
imbalance of Th1 cells and Th2 cells (Th1/Th2 re-
sponses), delayed eosinophil apoptosis, IgE-medi-
ated facilitated antigen presentation by epidermal 
dendritic cells (DCs), altered prostaglandin metab-
olism, and intrinsic defects in keratinocyte function 
(3). The concept of “extrinsic” vs “intrinsic” type of 
atopic dermatitis is attractive (49). The concept of 
AD starting with Th2 inflammation, becoming Th1 
inflammation in chronicity, and finally progressing 
to an autoimmune disease with IgE antibodies 
against autologous epidermal proteins is impor-
tant. There is evidence for exogenous AD elicita-
tion by contact with aero- or food allergens. Re-
cent investigations show that epidermal LCs bind 
IgE via different receptors, especially the high-af-
finity receptor, which is more strongly expressed in 
lesional skin in AD than in other inflammatory skin 
diseases. The functional expression of costimula-
tory molecules on antigen-presenting cells (APCs) 
such as dendritic cells (DCs) may be a key event 
in the pathogenesis of AD, although their role in 
the onset and maintenance of AD is not well es-
tablished. Costimulatory molecules on LCs and 
inflammatory dendritic epidermal cells (IDECs) 
might play a role in the pathogenesis of AD (49).  
Epidermal keratinocytes in AD patients produce 
and release proinflammatory cytokines and che-
mokines as a reaction to skin injury by environ-
mental allergens, scratching, or microbial toxins.  
 As immunologic dysregulation is a possible 
key defect in AD, the expression of different immu-
nologic parameters and costimulatory molecules 
such as integrins and selectins has been studied 
in AD patients (49). The adhesion molecules E-
selectin, P-selectin, ICAM-1 and the expression 
of vascular endothelial cell adhesion molecules 
1 (VCAM-1) are preferentially expressed on ac-
tivated endothelium in the dermis of AD patients 
(50,51).
 Keratinocytes, mast cells and DCs release cy-
tokines such as tumor necrosis factor α (TNF-α) 
and IL-1 (3). These cytokines bind to receptors on 
vascular endothelium, and induce the expression 
of adhesion molecules on VCAM-1 and facilitate 
the extravasation of inflammatory cells into the 
skin (3,32,33). LCs produce IL-16 which is a che-
moattractant cytokine for Th cells (3). Chemokines 
play a central role in AEDS. IL-16 has been de-
scribed as the main cytokine involved in CD4+ cell 
recruitment during inflammation (52).
 Immune responses in AD include a biphasic 
pattern of T-cell activation. There are different im-
munologic manifestations in the unaffected skin, 
acute skin and chronic AD skin. Deep seawater in-
take improves skin symptoms and mineral imbal-
ance, and decreases serum IgE levels and IgE-in-
ducing cytokines, IL-4, IL-13 and IL-18 in patients 
with AEDS, whereas distilled water intake fails to 
do so (53).
 NONLESIONAL AD SKIN
 Nonlesional AD skin shows sparse dermal 
perivascular cellular infiltrate that consists primar-
ily of T lymphocytes. Immunohistologic analysis 
shows a significantly greater number of Th2 cells 
expressing IL-4 and IL-13 but not IL-5 and IFN-γ 
messenger ribonucleic acid (mRNA) compared to 
normal nonatopic skin (3,54,55).
 ACUTE AD SKIN
 Acute AD skin shows sparse epidermal infil-
trate, which primarily consists of T lymphocytes, 
and there is marked perivenular inflammatory cell 
infiltrate in the dermis consisting predominantly 
of Th lymphocytes and in less number of LCs, 
IDECs and macrophages (3,56). Immunohisto-
logic analysis of cells shows a significant increase 
in the number of cells expressing IL-4, IL-5 and 
IL-13 mRNA but not IFN-γ and IL-12 mRNA com-
pared to nonlesional AD skin or normal nonatopic 
skin (3,54,57). However, acute skin lesions have 
a predominance of IL-4 and IL-13 expression (3). 
This is called Th2-type cytokine pattern (54). The 
authors demonstrated specific regulatory function 
of CD30+ T cells in acute AD, in accordance with 
the results reported by Caproni et al. (58,59).
 Recently, the influx of CD4+ lymphocytes has 
been related to the upregulation of IL-16 in AEDS 
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skin lesions. The presence of circulating beta-che-
mokines (Eotaxin and RANTES) and IL-16, which 
were investigated in children with AEDS, corre-
lates with the disease severity (52). Soluble CD30 
(sCD30) in peripheral blood is a marker of Th2 im-
mune response related to AEDS disease activity 
(52), and so is the presence of CD30 molecules in 
the skin (58). Keratinocyte-derived thymic stromal 
lymphopoietin (TSLP) and epidermal DC derived 
IL-10 and IL-4 stimulate Th differentiation into Th2 
(3). There is also overexpression of IL-16 (3). IL-
16 is an LCs cytokine that attracts Th cells in acute 
lesions and therefore plays a role in the initiation 
of inflammation (3,54,60).  IL-13 and IL-4 elevate 
IgE levels, induce switching to IgE synthesis , and 
also induce the expression of vascular adhesion 
molecule-1 (3,54). Therefore, they may play a role 
in the migration of eosinophils and mononuclear 
cells in acute AD skin lesions (3,61). IL-4 also in-
hibits the production of IFN-γ. IL-5 plays an impor-
tant role in differentiation, vascular adhesion and 
survival of eosinophils. Eosinophils also intermedi-
ate and release cytotoxic granules and contribute 
to tissue injury but also modulate T cell function by 
its own cytokines. Th2-type cytokines are involved 
in the initiation of AD (54).
 There is an elevated production of prostaglan-
din E2 (PGE2) by peripheral monocytes. PGE2 
has at least two potential roles in the initiation of 
AD. Firstly, it reduces IFN-γ production by T helper 
cells, thereby favoring the initial, dominant Th2 
immune response. Secondly, it directly enhanc-
es IgE production by B lymphocytes with an in-
creased secretion of IL-4, IL-5 and IL-13. Mast cell 
chymase may induce eosinophil infiltration into AD 
lesional skin.
 CHRONIC AD SKIN
 Chronic AD skin shows IgE-bearing LCs and 
IDECs in the epidermis. Dermal mononuclear infil-
trate is predominated by macrophages, whereas T 
cells, eosinophils and mast cells are also increased 
but to a lesser extent. Immunohistologic analysis 
of cells shows a significant increase in the number 
of cells expressing a significantly greater number 
of  IL-13, IL-4, IL-5 and IFN-γ mRNA cells than in 
normal or nonlesional skin of AD patients, while 
there is a greater number of  IL-5, IL-12, GM-CSF 
and IFN-γ mRNA cells and fewer IL-13 and  IL-4 
mRNA compared to acute AD skin lesions (3,54). 
T cells constitute the majority of IL-5 expressing 
cells. There is also a significantly greater number 
of activated IL-5 mRNA-expressing eosinophils 
than in acute lesions (3,54). IL-11, a profibrotic 
cytokine, is also increased with the resulting colla-
gen deposition during chronic AD (3). IL-5 plays an 
important role in differentiation, vascular adhesion 
and survival of eosinophils. IL-12 is produced in 
eosinophils and/or macrophages, and its function 
is to induce Th cells to differentiate and mature 
into Th1 cells (54,62). Therefore, IL-12 may ac-
count for the termination of the Th2-type cytokine 
pattern, which is observed in acute lesions, and it 
also initiates the switch to Th1 cell development in 
chronic lesions (54,62,63).  
 GM-CSF, produced by keratinocytes, enhanc-
es eosinophil and macrophage survival in chronic 
lesions (54). Therefore, Th1-type cytokines (IL-2 
and IFN-γ) account for the persistence of inflam-
matory response in AD (54).
 In chronic AD lesions LCs are present in in-
creased numbers and have increased amounts 
of IgE bound to high-affinity surface receptors. 
LCs have been shown to be hyperstimulatory to T 
helper cells and can activate T helper cells to Th2 
phenotype in the initiating phase of the disease.
Antigen-presenting cells, IgE-bearing LCs and 
IDECs, express the high affinity IgE receptor 
(3,56). The increased expression of FcεRI on DCs 
in AD skin is due to the enhanced expression of 
FcεRI γ chain and is preserved by increased IgE 
levels (3,64). LCs and IDECs play an important 
role in allergen presentation to Th2 and Th1 cells, 
respectively (3,65). LCs with FcεRI-bound IgE en-
able the capture, processing and antigen presen-
tation of allergens to T cells in atopic skin. They 
may migrate to lymph nodes and stimulate naive 
T cells to expand the pool of Th2 cells. Therefore, 
the immediate (IgE-mediated mast cell type), late 
(IgE-mediated Th2-type) and delayed (IgE-inde-
pendent Th1 type) allergic reactions are involved.
 CONCLUSION
 Although there is ample new information on 
the pathogenesis of AD, the basic underlying etiol-
ogy remains elusive. Despite great progress, the 
pathogenesis of AD is still incomplete and the clin-
ical importance of various changes in the immune 
system parameters is still unclear. In the future, we 
hope the development of new therapeutic AD ap-
proaches will be aimed at specific targets. Nowa-
days, the main directions of current therapy for AD 
are suppression of inflammation, avoidance and 
control of trigger factors, and improvement of skin 
care. Additional studies are needed to elucidate 
the role of factors involved in the pathogenesis of 
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